Drugs / Poliorix™
Poliorix™
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00937404 | Aug → Nov 2009 | poliomyelitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01449812 | Oct 2011 → Jan 2012 | diphtheria, haemophilus infectious disease, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01021293 | Nov 2009 → Jul 2010 | poliomyelitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01831050 | May 2013 → Apr 2014 | poliomyelitis | Fidec Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01094171 | Dec 2010 → Oct 2012 | poliomyelitis | GlaxoSmithKline | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01106092 Comparator | May → Sep 2010 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT01086423 Comparator | Mar → Nov 2010 | diphtheria, haemophilus infectious disease, poliomyelitis, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00547248 Background | Oct 2007 → May 2008 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00344318 Background | Aug 2006 → Apr 2007 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Poliorix | “Two pilot safety studies and two larger immunogenicity trials evaluated the non-inferiority of IPV (Poliorix™, GSK Vaccines, Belgium) versus OPV in infants and booster...” PMID 26873055 ↗ Feb 2016 |
| Known as | Glaxo SmithKline IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01831050 ↗ |
| Known as | IPV | “received 3 doses of Poliorix™ (IPV) vaccine at 2, 3 and 4 months of age” NCT01021293 ↗ |
| Known as | PoliorixTM | “Subjects received 3 primary doses of PoliorixTM and InfanrixTM vaccines at 3, 4.5 and 6 months of age.” NCT01094171 ↗ |
| Modality | Vaccine | “Subjects aged 6-12 weeks from Poland receiving Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 2, 4, 6 months of age.” NCT00344318 ↗ |
| Route | Intramuscular | “administered intramuscularly into the upper right side of the thigh” NCT00937404 ↗ |